PharVision Advisers’s BioLife Solutions BLFS Stock Holding History

PharVision Advisers’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,389	Closed	-$316K	–	714
2025 Q3	$316K	Buy	+12,389	New	+$294K	0.18%	199

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PharVision Advisers's BLFS Position: Q4 2025 in Review

PharVision Advisers sold out of BioLife Solutions (BLFS) in Q4 2025, closing a stake of 12,389 shares — an estimated $316K sold.

PharVision Advisers first reported a position in BLFS in Q3 2025 and held it in 1 quarter. The position peaked at $316K in Q3 2025. 187 funds tracked by Wall St. Rank hold BLFS as of Q4 2025.

PharVision Advisers reported no remaining BioLife Solutions position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 12,389 BioLife Solutions shares in Q4 2025, an estimated $316K.
PharVision Advisers first reported a position in BioLife Solutions in Q3 2025 and held it in 1 quarter.
PharVision Advisers's BioLife Solutions position peaked at $316K in Q3 2025.
187 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.